{"id":57961,"date":"2023-08-29T07:04:43","date_gmt":"2023-08-29T05:04:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/"},"modified":"2023-08-29T07:04:43","modified_gmt":"2023-08-29T05:04:43","slug":"innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/","title":{"rendered":"Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update"},"content":{"rendered":"<div>\n<p>MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;<a href=\"https:\/\/twitter.com\/hashtag\/ANKET?src=hash\" target=\"_blank\" rel=\"noopener\">#ANKET<\/a>&#8211;Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201c<b>Innate<\/b>\u201d or the \u201c<b>Company<\/b>\u201d) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. In addition, the Company will hold a conference call on Thursday, September 14, 2023, at 2 p.m. CEST \/ 8 a.m. EDT, to give an update on business progress during the first half of 2023.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230828906538\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230828906538\/en\/1245155\/21\/INNATEvertnoirDS.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20230828906538\/en\/1245155\/4\/INNATEvertnoirDS.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230828906538\/en\/1245155\/22\/INNATEvertnoirDS.jpg\"><\/a><\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Citi\u2019s 18th Annual BioPharma Conference<br \/>\n<br \/><\/b><b>Event Date: <\/b>September 6 \u2013 7, Boston<\/li>\n<li>\n<b>H.C. Wainwright 25th Annual Global Investment Conference<br \/>\n<br \/><\/b><b>Event Date: <\/b>September 11 \u2013 13, New-York<\/li>\n<li>\n<b>Morgan Stanley 21st Annual Global Healthcare Conference<br \/>\n<br \/><\/b><b>Event Date: <\/b>September 11 \u2013 13, New-York<\/li>\n<li>\n<b>First Half 2023 Financial Results and Business Update<br \/>\n<br \/><\/b><b>Event Date: <\/b>September 14 \u2013 Conference call and Webcast<\/li>\n<\/ul>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p>\n\u00a0<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b><span class=\"bwuline\">Details for the First Half 2023 Business Update Virtual Event<\/span><\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>Thursday, September 14, 2023, at 2 p.m. CEST \/ 8 a.m. EDT<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>The live webcast will be available at the following link:<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F859850812&amp;esheet=53545305&amp;newsitemid=20230828906538&amp;lan=en-US&amp;anchor=https%3A%2F%2Fevents.q4inc.com%2Fattendee%2F859850812&amp;index=1&amp;md5=980b590988263c52c36873995542d6fe\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/events.q4inc.com\/attendee\/859850812<\/a><\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\nParticipants may also join via telephone using the following registration link: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fregistrations.events%2Fdirect%2FQ4E60903&amp;esheet=53545305&amp;newsitemid=20230828906538&amp;lan=en-US&amp;anchor=https%3A%2F%2Fregistrations.events%2Fdirect%2FQ4E60903&amp;index=2&amp;md5=d5c2d934b2711684c80a46ec93498499\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/registrations.events\/direct\/Q4E60903<\/a><\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\n<i>This information can also be found on the Investors section of the Innate Pharma website, <\/i><a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com&amp;esheet=53545305&amp;newsitemid=20230828906538&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=3&amp;md5=6b8d4dff08b214ef36901a3c47488494\" rel=\"nofollow noopener\" shape=\"rect\"><i>www.innate-pharma.com<\/i><\/a><i>. A replay of the webcast will be available on the Company website for 90 days following the event.<\/i><\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>About Innate Pharma<\/b><\/p>\n<p>\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET<sup>\u00ae<\/sup> (<b>A<\/b>ntibody-based <b>NK<\/b> cell <b>E<\/b>ngager <b>T<\/b>herapeutics) proprietary platform.<\/p>\n<div class=\"bwpagebreakafter\"><\/div>\n<p>\nInnate\u2019s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET<sup>\u00ae<\/sup> multi-specific NK cell engagers to address multiple tumor types.<\/p>\n<p>\nInnate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.<\/p>\n<p>\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n<p>\nLearn more about Innate Pharma at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.innate-pharma.com%2F&amp;esheet=53545305&amp;newsitemid=20230828906538&amp;lan=en-US&amp;anchor=www.innate-pharma.com&amp;index=4&amp;md5=4ae3b210f6d3da523dadc4d9ad17bad9\" rel=\"nofollow noopener\" shape=\"rect\">www.innate-pharma.com<\/a> and follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FInnatePharma&amp;esheet=53545305&amp;newsitemid=20230828906538&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=74cb1df15d750fa4a110530821546bfd\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Finnate-pharma%2F&amp;esheet=53545305&amp;newsitemid=20230828906538&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=34bf93be64520893cd983feeb778b0b0\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a>.<\/p>\n<p>\n<b>Information about Innate Pharma shares<\/b><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth70\">\n<tr>\n<td class=\"bwvertalignt bwpadl0 bwwidth30\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignl bwcellpmargin\">\n<b>ISIN code<\/b><br \/><b>Ticker code<\/b><br \/><b>LEI<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0 bwwidth70\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nFR0010331421<\/p>\n<p class=\"bwcellpmargin\">\nEuronext: IPH Nasdaq: IPHA<\/p>\n<p class=\"bwcellpmargin\">\n9695002Y8420ZB8HJE29<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Disclaimer on forward-looking information and risk factors<\/b><\/p>\n<p>\nThis press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including \u201cbelieve,\u201d \u201cpotential,\u201d \u201cexpect\u201d and \u201cwill\u201d and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s commercialization efforts and the Company\u2019s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company&#8217;s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amf-france.org&amp;esheet=53545305&amp;newsitemid=20230828906538&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.amf-france.org&amp;index=7&amp;md5=a605d6b54d3cd9050906e2f875f1933f\" rel=\"nofollow noopener\" shape=\"rect\">http:\/\/www.amf-france.org<\/a> or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2022, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.<\/p>\n<p>\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b><span class=\"bwuline\">Investors<\/span><\/b><br \/><b>Innate Pharma<\/b><br \/>Henry Wheeler<br \/>\n<br \/>Tel.: +33 (0)4 84 90 32 88<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;&#111;&#x3a;&#x48;&#101;n&#x72;&#121;&#46;&#x77;&#x68;&#101;e&#x6c;&#101;r&#x40;&#x69;&#110;n&#x61;&#116;e&#x2d;&#x70;&#104;a&#x72;&#109;a&#x2e;&#x66;&#114;\" rel=\"nofollow noopener\" shape=\"rect\">He&#110;&#114;&#x79;&#x2e;&#x77;&#x68;ee&#108;&#101;&#x72;&#x40;&#x69;&#x6e;na&#116;&#101;&#45;&#x70;&#x68;&#x61;&#x72;ma&#46;&#102;&#x72;<\/a><\/p>\n<p>\n<b><span class=\"bwuline\">Media Relations<\/span><\/b><br \/><b>NewCap<\/b><br \/>Arthur Rouill\u00e9<br \/>\n<br \/>Tel.: +33 (0)1 44 71 00 15<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#x69;&#x6c;t&#111;&#x3a;&#x69;n&#110;&#97;&#x74;&#x65;&#64;&#110;&#x65;&#x77;c&#97;&#x70;&#x2e;e&#117;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#x6e;&#x6e;&#x61;&#x74;&#101;&#64;&#110;&#101;wca&#x70;&#x2e;&#x65;&#x75;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;#ANKET&#8211;Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. In addition, the Company will hold a conference call on Thursday, September 14, 2023, at 2 p.m. CEST \/ 8 a.m. EDT, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57961","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;#ANKET&#8211;Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. In addition, the Company will hold a conference call on Thursday, September 14, 2023, at 2 p.m. CEST \/ 8 a.m. EDT, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-29T05:04:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230828906538\/en\/1245155\/21\/INNATEvertnoirDS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update\",\"datePublished\":\"2023-08-29T05:04:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\\\/\"},\"wordCount\":700,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230828906538\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\\\/\",\"name\":\"Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230828906538\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"datePublished\":\"2023-08-29T05:04:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230828906538\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230828906538\\\/en\\\/1245155\\\/21\\\/INNATEvertnoirDS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update - Pharma Trend","og_description":"MARSEILLE, France&#8211;(BUSINESS WIRE)&#8211;#ANKET&#8211;Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. In addition, the Company will hold a conference call on Thursday, September 14, 2023, at 2 p.m. CEST \/ 8 a.m. EDT, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/","og_site_name":"Pharma Trend","article_published_time":"2023-08-29T05:04:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230828906538\/en\/1245155\/21\/INNATEvertnoirDS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update","datePublished":"2023-08-29T05:04:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/"},"wordCount":700,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230828906538\/en\/1245155\/21\/INNATEvertnoirDS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/","url":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/","name":"Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230828906538\/en\/1245155\/21\/INNATEvertnoirDS.jpg","datePublished":"2023-08-29T05:04:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230828906538\/en\/1245155\/21\/INNATEvertnoirDS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230828906538\/en\/1245155\/21\/INNATEvertnoirDS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/innate-pharma-announces-its-participation-to-upcoming-investor-conferences-and-conference-call-for-first-half-2023-business-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57961"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57961\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}